Becton, Dickinson and Company

(New York Stock Exchange)
Back to all articles
Somewhat Bearish -40

Argus Lowers its Price Target on Becton, Dickinson and Company (BDX) to $180 from $230

AI-generated analysis

- πŸ“‰ Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180 as of March 23, 2026.

- ⭐ The firm maintained a Buy rating for the company following its strategic transition toward a pure-play medical technology model.

- πŸ”„ This pivot involves the spin-off of its Biosciences and Diagnostics Solutions businesses, reshaping the company's core operations.

- πŸ’Ή BDX currently trades at 11.5 times forward earnings, which is significantly below the 20.4x average for the broader MedTech coverage universe.

- πŸš‘ The FDA granted 510(k) clearance for Surgiphor 1000mL, a new antimicrobial irrigation system designed for powered lavage to enhance surgical safety.

- πŸ“Š In its latest quarter, Becton, Dickinson and Company reported adjusted earnings per share of $2.91, beating the analyst consensus of $2.81.

- πŸ’° Revenue for the period reached $5.3 billion, surpassing the expected estimate of $5.15 billion.

- πŸ—£οΈ CEO Tom Polen characterized the results as "stronger-than-expected," attributing the performance to execution and growth in key markets.

- πŸ”„ Management emphasized that the company is "fully pivoting to New BD" with a focus on innovation, productivity, and long-term expansion.

- πŸ”¬ Becton, Dickinson and Company develops and sells medical devices, laboratory equipment, and diagnostic products on a global scale.

- πŸ“‰ Analysts at Argus view the stock as undervalued relative to peers due to its lower valuation multiple post-spin-off.

- ⚠️ The article notes that the spin-off marks a significant structural change reducing exposure to certain diagnostics segments.

- 🏭 The company is now concentrating its efforts on core medtech operations following the separation of non-core assets.

Bullish Signals
  • Becton, Dickinson and Company (NYSE:BDX) is recognized as one of the 7 Most Undervalued Blue Chip Stocks to Invest In.
  • Argus maintained a Buy rating on BDX despite lowering the price target, citing the company's successful transition toward a pure-play medtech model following the spin-off of its Biosciences and Diagnostics Solutions business.
  • The stock trades at about 11.5 times forward earnings, which is significantly below the 20.4 times average for its MedTech coverage universe, highlighting its undervalued status.
  • On March 23, 2026, the company received FDA 510(k) clearance for Surgiphor 1000mL, the first 1000 mL antimicrobial irrigation system designed for powered lavage aimed at improving surgical efficiency and safety.
  • Becton, Dickinson and Company reported Q1 adjusted EPS of $2.91, beating the $2.81 consensus estimate, on revenue of $5.3B versus $5.15B expected.
  • CEO Tom Polen described Q1 results as 'stronger-than-expected' performance driven by execution and growth across key markets.
  • The company is fully pivoting to 'New BD' following its portfolio changes, with a clear focus on innovation, productivity, and long-term growth.
Risk Factors
  • Argus lowered its price target on Becton, Dickinson and Company (BDX) from $230 to $180 on March 23, 2026, indicating a significant reduction in expected upside.
Full Analysis
Argus Research has downgraded its price target for Becton, Dickinson and Company (NYSE:BDX) from $230 to $180 while maintaining a Buy rating, driven by the company's strategic shift toward a pure-play medical technology model following the spin-off of its Biosciences and Diagnostics Solutions segments. The analyst firm highlights that the stock currently trades at 11.5 times forward earnings, which is significantly below the 20.4x average for comparable companies in its MedTech coverage universe, suggesting it remains undervalued despite the rating adjustment. This financial restructuring aligns with CEO Tom Polen's comments on stronger-than-expected performance in Q1, where adjusted earnings per share of $2.91 exceeded analyst expectations of $2.81, and revenue reached $5.3 billion against a forecast of $5.15 billion. The company continues to innovate within its new strategic direction, evidenced by recent FDA 510(k) clearance for the Surgiphor 1000mL antimicrobial irrigation system, the first of its kind designed for powered lavage to enhance surgical efficiency and safety. This approval underscores the management's focus on innovation and growth in key markets as part of the transition to what they call "New BD." While Argus acknowledges BDX's investment potential, it contrasts this with a broader market view that certain AI stocks currently offer greater upside, though this specific comparison does not alter the positive assessment of BDX's current valuation metrics relative to peers.